Oncolytics Biotech Inc T.ONC

Pfizer

[fasttrack5]

Pharmaceutical giant Pfizer has inked a deal to house its growing oncology business in a new, palatial San Diego estate overlooking the ocean. The drugmaker recently signed a 15-year lease for 230,000 square feet of space at the Torrey View campus, currently under construction.

[Noteable]

March 19, 2024 - https://www.sandiegouniontribune.com/business/story/2024-03-19/pfizer-inks-large-deal-for-lab-space-at-new-torrey-view-campus-in-san-diego Pfizer Oncology has signed a 15-year, 230,000-square foot lease at the Torrey View life science campus nearing completion in San Diego by Breakthrough Properties, which is a joint venture between Tishman Speyer and biotechnology

[Noteable]

Pfizer is taking a deeper dive into Precision Medicine which follows Pfiser's CEO Chris Bishoff announcement in January 2024 that the company's oncology division plans to shift to biologic drugs as its main source of revenue, and away from small molecules, increasing the proportion of those biologic treatments from 6% to 65% by 2030. https://www.cnbc.com/2024/03/10/pfizer-is-betting-big

[Noteable]

Pfizer executives last week said that their antibody drug conjugate (ADC) Padcev had “mega-blockbuster” potential, which the company defines as raking in annual sales of more than $3 billion.  In December 2023 Pfizer's Padcev was approved in combination with the immune checkpoint inhibitor Keytruda for the treatment of Advanced Bladder Cancer. https://www.pfizer.com/news/press-release

[ENEMENEMYNEMO]

Is ONC presenting anything at the AACR next week?

[Noteable]

Jan. 24, 2024-- CG Oncology, Inc. a late-stage clinical biopharmaceutical company is focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.(superficial non-muscle invasive bladder cancer).

[Noteable]

For PADCEV and our related ADC technology, we own, co-own or have licensed rights to twelve patents in the United States and Europe that will expire between 2022 and 2031. Of these patents, we own or co-own ten patents and have licensed rights to two patents. For PADCEV and our related ADC technology, we own, co-own or have licensed rights to twelve patents

[Noteable]

Stockhouse is messing up the posting format and the below message should read:  For PADCEV and Pfizer's now owned Seagen acquired related ADC technology, Pfizer now owns, co-owns or has licensed rights to twelve patents in the United States and Europe that will expire between 2022 and 2031. Of these patents, Pfizer/Seagen owns or co-owns ten patents and have licensed

[Noteable]

In September 2020, Merck & Co announced it would purchase $1 billion of Seagen's common stock, with both companies co-developing lead ADC treatment: ladiratuzumab vedotin The antibody drug conjugate (ADC) ladiratuzumab vedotin had been in early stage clinical trials for metastatic triple negative breast cancer, which ONCY had also run a clinical trial involving pelareorep

[Noteable]

Pfizer paid US$43 Billion for Seagen's 3 approved drugs and the company's ADC platform. https://s21.q4cdn.com/327105422/files/doc_financials/2020/q4/5dafdb1c-8e23-4019-b892-6a6fa661ee0a.pdf

[Noteable]

"The most appealing partners for ADCs are those that offer additive or synergistic effects on tumor cells or their microenvironment without unacceptable overlapping toxicities." However the 2020 Roche sponsored KATE2 study, the only published randomized trial testing an ADC plus an ICI, compared trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in

[Noteable]

Research on Fc-inert PD-L1×4-1BB bispecific antibody (mbsAb-PD-L1×4-1BB) is providing proof-of-concept data that is showing enhanced anti-tumor activity. . Anti-tumor activity was associated with increased tumor-specific CD8+ T cells and reduced regulatory T cells within the tumor microenvironment and tumor-draining lymph nodes.  In contrast Avelumab (MSB

[Noteable]

As the first ADC approved for breast cancer, T-DM1 has been widely used in HER2+ breast cancer patients. However, some patients experience relapse or progress on T-DM1 treatment. Such resistance may develop after responding to the treatment (acquired resistance) or exist from the beginning (de novo resistance). The antitumor activity of ADCs depends on both the antibody and the payload, while the

[Noteable]

Pfizer Unveils Priorities for Its New Oncology Organization This new Pfizer initiative will be fueled partly by steady growth in cancer prevalence and incidence.  ‘We have a clear strategy focused on three core scientific modalities and four main types of cancer, where we have the deep expertise and knowledge to advance our leadership. With many significant catalysts expected through the

[Noteable]

Pfizer will now build up its biologics business, newly appointed Chief Oncology Officer Chris Boshoff said in a statement, adding that this strategic positioning—combined with several “significant catalysts” starting in 2025—will help Pfizer’s oncology franchise be a “critical driver of potential long-term sustainable sales and profit growth” for the company.

[13X2413]

I can only hope you're insinuating that ONC vacated their San Diego location to be a tenant in these fancy new digs. 

[CaseyL]

I certainly hope so. I could see the platform being purchased regardless of who has the better results. It's a platform after all. I could see Pfizer purchasing with Roche having the blockbuster results. I just hope this grand finale ends soon 

[Noteable]

https://stockhouse.com/companies/bullboard/oncy/oncolytics-biotech-inc?postid=36024920

[Noteable]

  March 04, 2024 - IRA Drives Pfizer's Decision to Focus on Biologics, Not Small Molecules. https://www.biospace.com/article/ira-drives-pfizer-s-decision-to-focus-on-biologics-not-small-molecules/

[Noteable]

May 01, 2024 - Drug Companies, VCs Rethink R&D Strategies as IRA Stands Strong in Court   Drug development had already been trending toward biologics. This drug class received 30% more VC funding in 2022 than small molecule candidates, noted John Stanford, executive director of life sciences venture capital coalition Incubate—but the gap jumped to 50% in 2023, and Stanford contends that

[Noteable]

May 08, 2024 - Pfizer Gene Therapy DMD Patient Dies.  A young boy with Duchenne muscular dystrophy (DMD) participating in Pfizer’s phase 2 gene therapy trial has died.  This isn't the first death to occur among a patient who has received PF-06939926. Back in December 2021, Pfizer reported the death of a young male patient in a phase 1 DMD trial. The company paused screening